Clinical Trials Browser

Phase 1 × INDUSTRY × Lapatinib × Clear all

Breast Neoplasms

NCT01199367 2024-04-25

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Phase 1 Terminated

11 enrolled

Breast

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Phase 1 Terminated

53 enrolled

Breast

Breast Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

65 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1 Completed

31 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00371488 2018-08-31

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Phase 1 Completed

11 enrolled

Breast

Breast Neoplasms

NCT00462956 2018-08-31

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Phase 1 Completed

59 enrolled

Breast

Breast Neoplasms

NCT00790816 2018-02-28

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Phase 1 Completed

500 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00536809 2017-12-18

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Phase 1 Completed

12 enrolled 6 charts

Gastrointestinal

Colorectal Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase 1 Completed

52 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00258050 2017-12-06

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Phase 1 Completed

24 enrolled

Breast

Breast Neoplasms

NCT00158782 2017-11-17

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Phase 1 Completed

75 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00169533 2017-11-17

Rollover Study Of Lapatinib In Cancer Patients

Phase 1 Completed

31 enrolled

Breast

Breast Neoplasms

NCT00388076 2017-11-17

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Phase 1 Completed

86 enrolled

Breast

Breast Neoplasms

NCT00528281 2017-11-17

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Phase 1 Completed

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00650910 2017-11-17

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Phase 1 Completed

17 enrolled

Breast

Breast Neoplasms

NCT00849329 2017-11-14

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Phase 1 Completed

12 enrolled

Breast

Breast Neoplasms

NCT00359190 2017-11-13

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Phase 1 Completed

28 enrolled

Breast

Breast Neoplasms

NCT00516672 2017-11-13

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Phase 1 Completed

30 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00821054 2017-11-13

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Phase 1 Completed

24 enrolled

Breast

Breast Neoplasms

NCT00996762 2017-11-13

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Phase 1 Completed

158 enrolled

Breast

Breast Neoplasms

NCT01290354 2017-11-13

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Phase 1 Completed

10 enrolled

Tumor-Agnostic

Neoplasms

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 1 Terminated

13 enrolled 13 charts

Breast

Breast Neoplasms

NCT00682279 2015-04-17

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

MK-2206-015

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Rollover Study Of Lapatinib In Cancer Patients

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors